Jonjones325 Friday, 04/05/19 06:34:29 PM Re: Jonjones325 post# 188407 Post # of 231002 A little more. He said he thinks that 2-73 would work on Schizophrenia but we don't have money for all these trials so we're piggy backing on ERP to be involved but not invest in a trial. He said if we had the money, we'd be running a ton of trials. He also said that we might get our own sales team for Rett for since it's a manageable sized market but due to the massive size of Alz and PDD, we'll need a partner. If he didn't expect success, he wouldn't be talking about commercialization and wouldn't waste good money on stockpiling a supply for it. IMO of course.